Abstract
Only recently have differences in the real-world effectiveness of new oral anticoagulants (NOAC) come to light. The objective of this study was to examine differences in clinical outcomes and cost of NOAC for stroke prophylaxis in patients with non-valvular atrial fibrillation (NVAF). Retrospective
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
